Q-omics provides the consensus-scored POLR2A profile across patient tissues and cancer cell-line models. POLR2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POLR2A is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, POLR2A protein abundance shows 30,279 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where POLR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2A survival associations across molecular data types. POLR2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2A RNA expression–survival associations across cancer types. High POLR2A expression shows unfavorable associations in ACC, SKCM and LUSC, but favorable associations in KIRC, SCLC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POLR2A RNA expression.
This table summarizes POLR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POLR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2A shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, CHOL, LUSC and LIHC. The HNSC box plot shows higher POLR2A RNA expression in tumor versus normal tissue (log2 FC = +0.814, t-test p < 0.001).
This table shows molecular features associated with POLR2A in patient tissues and cancer cell lines. In patient samples, POLR2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
